Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Differentiation of Insulin Secretion Patterns in Insulinoma

View through CrossRef
AbstractBackgroundIn patients with insulinoma, biochemical proof of inappropriately elevated insulin secretion during hypoglycemia is required prior to surgery. Because circulating insulin levels usually vary widely, we have used the combined OGTT‐fasting test to define new normative criteria for a retrospective systematic analysis.MethodsWe retrospectively analyzed insulin concentrations from OGTT‐fasting tests of 64 patients with surgically removed insulinomas. In addition, the response to intravenous somatostatin infusions was estimated. Normative criteria were defined to obtain comparable estimates of insulin concentrations: basal, glucose‐stimulated maximum, postglucose plateau, and secretory bursts.ResultsThree types of insulin secretion patterns were identified: (1) the autonomous secretion pattern (type 1, N = 17) with basal and post‐OGTT plateau insulin concentrations of approximately 50 mU/L, suppression after OGTT by 41%, virtual absence of distinctive secretory bursts, and resistance to somatostatin‐mediated suppression (25 %); (2) the inadequate suppression pattern (type 2, N = 28) with moderately elevated basal and post‐OGTT insulin concentrations of approximately 20 mU/L, suppression after OGTT by 73%, absence of secretory bursts, and incomplete somatostatin‐induced suppression (56 %); (3) the late‐burst secretion pattern (type 3, N = 19) with similar basal and post‐OGTT insulin concentrations of 17 mU/L, suppression after OGTT by 76%, true insulin bursts of Δ 13 ± 11 mU/L (184%), and nearly complete somatostatin‐induced suppression by 64%.ConclusionsBy means of a new normative analysis of the combined OGTT‐fasting test, three different patterns of insulin secretion can be described in patients with insulinoma: the autonomous secretion type, the inadequate suppression type, and the late‐burst secretion type.
Title: Differentiation of Insulin Secretion Patterns in Insulinoma
Description:
AbstractBackgroundIn patients with insulinoma, biochemical proof of inappropriately elevated insulin secretion during hypoglycemia is required prior to surgery.
Because circulating insulin levels usually vary widely, we have used the combined OGTT‐fasting test to define new normative criteria for a retrospective systematic analysis.
MethodsWe retrospectively analyzed insulin concentrations from OGTT‐fasting tests of 64 patients with surgically removed insulinomas.
In addition, the response to intravenous somatostatin infusions was estimated.
Normative criteria were defined to obtain comparable estimates of insulin concentrations: basal, glucose‐stimulated maximum, postglucose plateau, and secretory bursts.
ResultsThree types of insulin secretion patterns were identified: (1) the autonomous secretion pattern (type 1, N = 17) with basal and post‐OGTT plateau insulin concentrations of approximately 50 mU/L, suppression after OGTT by 41%, virtual absence of distinctive secretory bursts, and resistance to somatostatin‐mediated suppression (25 %); (2) the inadequate suppression pattern (type 2, N = 28) with moderately elevated basal and post‐OGTT insulin concentrations of approximately 20 mU/L, suppression after OGTT by 73%, absence of secretory bursts, and incomplete somatostatin‐induced suppression (56 %); (3) the late‐burst secretion pattern (type 3, N = 19) with similar basal and post‐OGTT insulin concentrations of 17 mU/L, suppression after OGTT by 76%, true insulin bursts of Δ 13 ± 11 mU/L (184%), and nearly complete somatostatin‐induced suppression by 64%.
ConclusionsBy means of a new normative analysis of the combined OGTT‐fasting test, three different patterns of insulin secretion can be described in patients with insulinoma: the autonomous secretion type, the inadequate suppression type, and the late‐burst secretion type.

Related Results

New and simple Ohmic definition of insulin resistance in lean and obese subjects
New and simple Ohmic definition of insulin resistance in lean and obese subjects
objective:: Insulin enhances the influx of glucose into cells. However, the relationship between glucose and insulin is complex and insulin sensitivity varies widely with age, ethn...
A Case of Insulin Resistance Secondary to Insulin Induced Localized Cutaneous Amyloidosis.
A Case of Insulin Resistance Secondary to Insulin Induced Localized Cutaneous Amyloidosis.
Abstract Abstract 4908 Insulin resistance can be a major problem in patients with diabetes mellitus. Although multiple reasons can result in this prob...
Unexplained Hypoglycemia in a Diabetic Patient Unveiling Insulinoma: A Case Report
Unexplained Hypoglycemia in a Diabetic Patient Unveiling Insulinoma: A Case Report
Background: Insulinomas are rare, typically benign, insulin-secreting neuroendocrine tumors with an incidence of 1–4 cases per million annually. They commonly present with Whipple’...
THE EFFECT OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION TREATMENT, INSULIN ANALOG, AND HUMAN INSULIN OF CHILDREN WITH DIABETES
THE EFFECT OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION TREATMENT, INSULIN ANALOG, AND HUMAN INSULIN OF CHILDREN WITH DIABETES
The aim of this study is to evaluate the cost-effectiveness of  continuous subcutaneous insulin infusion (CSII) to multiple daily insulin injection (MDI) either with analogues or w...
WILLINGNESS-TO-PAY FOR INSULIN IN DIABETES TREATMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS
WILLINGNESS-TO-PAY FOR INSULIN IN DIABETES TREATMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS
Background: Insulin treatment is necessary for all patients with type 1 diabetes and a subset of patients with type 2 diabetes. However, lifetime insulin treatment is relatively co...
Rosiglitazone inhibits the insulin‐mediated increase in PAI‐1 secretion in human abdominal subcutaneous adipocytes
Rosiglitazone inhibits the insulin‐mediated increase in PAI‐1 secretion in human abdominal subcutaneous adipocytes
Objective:  The aim of this study was to investigate the effect of insulin and an insulin‐sensitizing agent, rosiglitazone (RSG), on the production of plasminogen‐activator inhibit...
Detection of Insulin in Insulin-Deficient Islets of Patients with Type 1 Diabetes
Detection of Insulin in Insulin-Deficient Islets of Patients with Type 1 Diabetes
Type 1 diabetes (T1D) is related to the autoimmune destruction of β-cells, leading to their almost complete absence in patients with longstanding T1D. However, endogenous insulin s...
KELCH-3 (KLHL3): A Potential Regulator of Insulin-Induced Renal Haemodynamic Alterations in Obesity
KELCH-3 (KLHL3): A Potential Regulator of Insulin-Induced Renal Haemodynamic Alterations in Obesity
Background: The contribution of elevated insulin levels to renal disease in pre-diabetic obesity remains underappreciated, as glomerular ...

Back to Top